Date:10/27/2011

Net cash from (for) operating activities54,147(6,162)Cash Flows (For) From Investing Activities   Acquisitions of businesses, net of cash acquired(547,052)1,998Proceeds from sale of intangible assets and pipeline R&D projects10,500-   Additions to property and equipment(18,953)(9,194)Other(250)-Net cash for investing activities(555,755)(7,196)Cash Flows (For) From Financing Activities   Borrowings (repayments) of short-term debt, net980(7,476)   Net borrowings under accounts receivable securitization program55,00063,000Borrowings of long-term debt250,787-   Repayments of long-term debt-(95,000)Deferred financing fees(2,468)-   Excess tax benefit of stock transactions10,5789,465   Issuance of common stock5,8843,987   Repurchase of common stock(7,899)(8,168)   Cash dividends(6,535)(5,780)Net cash from (for) financing activities306,327(39,972)Effect of exchange rate changes on cash1,792(337)Net decrease in cash and cash equivalents(193,489)(53,667)Cash and cash equivalents of continuing operations, beginning of period310,104109,765Cash balance of discontinued operations, beginning of period--Cash and cash equivalents, end of period116,61556,098Less cash balance of discontinued operations, end of period--Cash and cash equivalents of continuing operations, end of period

$

116,615$

56,098Supplemental Disclosures of Cash Flow Information   Cash paid/received during the period for:Interest paid

$

3,240$

6,343Interest received

$

1,127$

1,977Income taxes paid

$

9,151$

29,856Income taxes refunded

$

768$

893See accompanying notes to condensed consolidated financial statements.PERRIGO COMPANYCONDENSED CONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share amounts)(unaudited)First Quarter20122011Net sales

$

725,295$

641,322Cost of sales497,716427,368Gross profit227,579213,954Operating expense
'/>"/>

SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix